Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMNANT
2023-510215-18-00Phase 3Authorised
- Sponsor
- Oslo University Hospital
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of bortezomib, lenalidomide, dexamethasone, daratumumab, carfilzomib and 1 more in multiple myeloma (MM) (3 arms), sponsored by Oslo University Hospital. Primary endpoints: MRD negativity after consolidation, Progression-free survival after second-line treatment and 1 more. Planned start Sep 2024; status: authorised.
02
Drugs
bortezomiblenalidomidedexamethasonedaratumumabcarfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2023-510215-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510215-18-00.